Theranostic Guided Riboflavin/UV-A Corneal Cross-linking
Key facts
- Who runs it
- Regensight
- Where
- Italy3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 50 people enrolled
- Started
- 27 Apr 2022
- Ended
- 26 Jan 2024
- Type of study
- Interventional
- Treatments tested
- Riboflavin/UV-A corneal cross-linking
- Record updated
- 11 February 2025
Who can take part
- Age
- 18 years to 40 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (16)Hide the full registry criteria
Who can take part
- criteria for inclusion in the clinical trial are those currently referred to as the golden standard for the treatment of corneal cross-linking. The criterion to determine progression of keratoconus is based on providing at least one of the following evidences:
- at least two Placido disk corneal topography measurements showing at least +1.00 D steepening of the Kmax value in the last year or longer interval period
- at least two manifest refraction measurements showing at least -0.50 D change in spherical equivalent refraction in the last year or longer interval period
- at least two central corneal thickness (CCT) measurements showing at least -10 µm change in in the last year or longer interval period
Who cannot take part
- Concomitant eye diseases
- History of herpetic keratitis
- Inflammatory eye diseases
- Anterior corneal curvature steeper than 63 D
- Corneal thickness thinner than 400 µm
- Corneal scarring
- Descemetocele
- Glaucoma
- Cataract
- Nistagmus
- Pregnancy
- Breast feeding
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a clinical study consisting of a study arm to validate accuracy and precision of the combined use of theranostic imaging biomarkers, riboflavin score and theranostic score, to assess and predict efficacy of corneal cross-linking in flattening the corneal topography Kmax value at 12-months postoperatively. The objective of the study is to assess the performance of the theranostic software module (Research Use Only) of a CE marked (CE1936) UV-A medical device, C4V CHROMO4VIS™, in order to validate its use for theranostic-guided corneal cross-linking treatment of keratoconus and corneal ectasia. The study hypothesis is that theranostic-guided riboflavin/UV-A corneal cross-linking with the C4V CHROMO4VIS™ system is safe and can estimate treatment efficacy during operation, regardless of treatment protocol, i.e., either with or without epithelial removal.
The group in the trial
- Riboflavin/UV-A corneal cross-linking monitored by theranostic software moduleTreatment being tested
One study arm receiving riboflavin/UV-A corneal cross-linking with either standard, epi-off, or transepithelial, epi-on, treatment protocol. Only one eye of each participant is designated as the study eye.
Treatment: Riboflavin/UV-A corneal cross-linking
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Assessment of Theranostic Guided Riboflavin/UV-A Corneal Cross-linking for Treatment of Keratoconus
- Publications
- Record updated
- 11 February 2025